-
公开(公告)号：US20250121058A1
公开(公告)日：2025-04-17
申请号：US18984106
申请日：2024-12-17
Applicant: GENENTECH, INC.
Inventor： Gail Lewis Phillips , Deepak Sampath , Ingrid Wertz
IPC: A61K39/395 , A61K31/496 , A61K31/635 , A61K39/00 , A61K45/06 , A61K47/68 , A61P35/00 , C07K16/32 , G01N33/574
Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
-
公开(公告)号：US20230330102A1
公开(公告)日：2023-10-19
申请号：US18310913
申请日：2023-05-02
Applicant: Genentech, Inc.
Inventor： Thomas Pillow , Jack Sadowsky , Leanna Staben , Steven Staben , Binqing Wei , Ingrid Wertz , Pragya Adhikari , Nicole Blaquiere , Peter Dragovich , Wayne Fairbrother
IPC: A61K31/551 , A61K47/54 , A61K47/68 , A61K47/65 , A61P37/06 , A61P35/00 , C07K16/28 , C07K16/32 , C12N9/00
CPC classification number: A61K31/551 , A61K47/545 , A61K47/68 , A61K47/65 , A61P37/06 , A61P35/00 , C07K16/2827 , C07K16/32 , C12N9/93 , C12Y203/02007
Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
-
公开(公告)号：US20240277838A1
公开(公告)日：2024-08-22
申请号：US18659241
申请日：2024-05-09
Applicant: GENENTECH, INC.
Inventor： Gail Lewis Phillips , Deepak Sampath , Ingrid Wertz
IPC: A61K39/395 , A61K31/496 , A61K31/635 , A61K39/00 , A61K45/06 , A61K47/68 , A61P35/00 , C07K16/32 , G01N33/574
CPC classification number: A61K39/39558 , A61K31/496 , A61K31/635 , A61K45/06 , A61K47/6803 , A61K47/6809 , A61K47/6851 , A61P35/00 , C07K16/32 , G01N33/57415 , G01N33/57446 , A61K2039/505 , A61K2300/00 , C07K2317/24 , C07K2317/73 , G01N2333/4703 , G01N2800/52
Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
-
公开(公告)号：US10898570B2
公开(公告)日：2021-01-26
申请号：US15849018
申请日：2017-12-20
Applicant: Genentech, Inc.
Inventor： Gail Lewis Phillips , Deepak Sampath , Ingrid Wertz
IPC: A61K39/395 , C07K16/32 , G01N33/574 , A61K47/68 , A61K31/635 , A61K45/06 , A61P35/00 , A61K31/496 , A61K39/00
Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
-
公开(公告)号：US20160375033A1
公开(公告)日：2016-12-29
申请号：US15194859
申请日：2016-06-28
Applicant: Genentech, Inc.
Inventor： Kyle Edgar , Lori Friedman , Deepak Sampath , Kyung Song , Ingrid Wertz , Timothy Wilson
IPC: A61K31/553 , G01N33/68 , G01N33/574 , A61K31/565
CPC classification number: A61K31/553 , A61K31/138 , A61K31/337 , A61K31/357 , A61K31/4196 , A61K31/565 , A61K31/573 , A61K31/7068 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57415 , G01N33/57484 , G01N33/6848 , G01N2333/47 , G01N2500/10 , G01N2800/52 , A61K2300/00
Abstract: Taselisib (GDC-0032) induces the degradation of mutant-p110 alpha protein. Methods for selecting patients with mutant PI3K tumors for treatment with taselisib are described.
Abstract translation: Taselisib（GDC-0032）诱导突变型p110α蛋白的降解。 描述了选择患有Taselisib治疗的突变型PI3K肿瘤患者的方法。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20160136295A1
公开(公告)日：2016-05-19
申请号：US14322065
申请日：2014-07-02
Applicant: GENENTECH, INC.
Inventor： Ingrid Wertz
CPC classification number: C12Q1/6886 , A61K47/6803 , A61K47/6851 , A61K47/6889 , C07K16/30 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/57484 , G01N2333/4703 , G01N2800/52 , G01N2800/7023
Abstract: Provided herein are biomarkers for predicting sensitivity to treating cancer with anti-tubulin chemotherapeutic agents.
Abstract translation: 本文提供用于预测用抗微管蛋白化学治疗剂治疗癌症的敏感性的生物标志物。
-
公开(公告)号：US11666581B2
公开(公告)日：2023-06-06
申请号：US16194897
申请日：2018-11-19
Applicant: Genentech, Inc.
Inventor： Thomas Pillow , Jack Sadowsky , Leanna Staben , Steven Staben , Binqing Wei , Ingrid Wertz , Pragya Adhikari , Nicole Blaquiere , Peter Dragovich , Wayne Fairbrother
IPC: A61K31/551 , A61K47/54 , A61K47/68 , A61K47/65 , A61P37/06 , A61P35/00 , C07K16/28 , C07K16/32 , C12N9/00
CPC classification number: A61K31/551 , A61K47/545 , A61K47/65 , A61K47/68 , A61P35/00 , A61P37/06 , C07K16/2827 , C07K16/32 , C12N9/93 , C12Y203/02007
Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
-
公开(公告)号：US20210213130A1
公开(公告)日：2021-07-15
申请号：US17129096
申请日：2020-12-21
Applicant: GENENTECH, INC.
Inventor： Gail Lewis Phillips , Deepak Sampath , Ingrid Wertz
IPC: A61K39/395 , C07K16/32 , G01N33/574 , A61K47/68 , A61K31/635 , A61K45/06 , A61P35/00 , A61K31/496
Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
-
公开(公告)号：US20190175612A1
公开(公告)日：2019-06-13
申请号：US16194897
申请日：2018-11-19
Applicant: Genentech, Inc.
Inventor： Thomas Pillow , Jack Sadowsky , Leanna Staben , Steven Staben , Binqing Wei , Ingrid Wertz , Pragya Adhikari , Nicole Blaquiere , Peter Dragovich , Wayne Fairbrother
Abstract: The subject matter described herein is directed to antibody-PROTAC conjugates (PACs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
-
公开(公告)号：US20180140700A1
公开(公告)日：2018-05-24
申请号：US15849018
申请日：2017-12-20
Applicant: Genentech, Inc.
Inventor： Gail Lewis Phillips , Deepak Sampath , Ingrid Wertz
IPC: A61K39/395 , A61K31/496 , A61K47/68 , C07K16/32 , A61P35/00 , G01N33/574
Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
